Clinical Trial

7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

Study acronym: TEMPO

Recruiting

Record status

This record was last updated January 14, 2025 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.

Summary

This is an experimental medicine, single-centre, observational test-retest study to evaluate Filgotinib's mechanism of analgesic action in RA patients. The investigators hypothesize that Filgotinib's mechanism of analgesic action is determined by at least two factors. The first is related to those CNS sensitization pathways seen in fibromyalgia, specifically DMN-insula brain functional connectivity and insular glutamate. The second is related to peripheral inflammation, specifically joint synovitis, blood cytokines/chemokines and DAN-LIPL functional brain connectivity. The CNS sensitization pain pathways related to fibromyalgia are more quickly modified compared to those related to peripheral inflammation and help explain Filgotinib's rapid onset of effect.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2023-01-16; most recent amendment 2025-01-13.

Status change: Not Yet Recruiting → Recruiting 2023-08-23

Trial Details

NCT Number	NCT05697159
Lead Sponsor	NHS Greater Glasgow and Clyde Collaborators: Lakefront Biotherapeutics NV
Conditions	Rheumatoid Arthritis, Sickness Behavior, Inflammatory Disease, Autoimmune, Pain, Chronic
Enrollment	20 participants
Start Date	2023-08-22
Primary Completion	2025-07-31 (estimated)
Study Completion	2025-10-31 (estimated)
Updated on ClinicalTrials.gov	2025-01-14